Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

May 13, 2021

NASDAQ US Health Care Pharmaceuticals earnings 27 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Thanks. Good afternoon, everybody, and welcome to our earnings call and business update for the first quarter of 2021. With me on today's call is Dr. Bill Forbes, who serves as Chief Development Officer at Trevi and will take questions once I finish my prepared remarks. Since our previous earnings call took place just 6 weeks ago, my focus will be on updating you about progress in clinical development and on reporting results for the first quarter. The furthest along of our clinical development programs targets pruritus in prurigo nodularis, or PN, a serious and debilitating condition marked by papules and nodules on the skin along with relentless, severe itching. At this time, there is no approved treatment for this condition. PN is a long-term illness, and when someone scratches repeatedly, the papules and nodules can expand and progressively worsen. Our estimate is that about 730,000 people globally have PN — 300,000 of them in the U.S., with the remaining 430,000 located in other parts of the world. Although other companies are pursuing biologics for PN as well, our candidate is the only oral, non-biologic option in late-stage development, and we think that could translate into a significant advantage in addressing this serious unmet need; a Phase 2b/3 study in this condition, which we call the PRISM trial, is currently underway. Enrollment for PRISM has begun across the U.S. and Europe. As of today, more than 60 sites are activated. The study's primary endpoint is a responder analysis based on itch intensity reduction measured by the Worst Itch Numerical Rating Scale following 12 weeks of blinded fixed dosing. We have randomized about 255 of the 360 planned subjects so far, which is greater than 70% of enrollment. Feedback from sites has been encouraging, and we continue to see a very high percentage — greater than 95% — of eligible subjects completing week 14 and rolling over into the open-label extension portion of the trial. Beyond providing us with safety information over the long run, this will also deliver useful efficacy findings tied to how skin heals and patients' quality of life. Our view is that a therapy able to hit the symptomatic goal of cutting itch could interrupt the cycle of scratching, and that in turn would let the skin heal and generate changes to the disease as time goes on. Regarding enrollment, we've got a strong roster of locations and are continually discovering and rolling out approaches that assist those sites in locating and signing up additional participants. We're still striving to wrap up enrollment during Q3 of this year, but we've broadened our guidance to the latter half of the year, acknowledging that sign-ups could decelerate a bit across July and August—especially with COVID rules loosening and more people eager to get out and travel again. Once we've finished enrolling participants, we'll put out an announcement. My hope is that when we come together for our following earnings call, there will be just a short stretch of enrollment left for the study. In addition to running the clinical trial, our development team is preparing for what comes next in order to move forward with this indication. It's thrilling to let you know that the FDA has recently given us Fast Track designation for this proposed indication. Fast Track designation exists to assist development in progressing and to accelerate the review of drugs addressing serious and life-threatening conditions, allowing an approved product to reach the market quickly. Let's move on to the second program in our clinical pipeline, focused on treating chronic cough among people who have idiopathic pulmonary fibrosis, or IPF. This illness is severe and progressive, characterized by scarring within lung tissue. One of its most debilitating hallmark symptoms is a persistent cough, affecting somewhere between 70% and 85% of those with the disease, and no therapies have won approval for it. Within the U.S., our estimate is that about 130,000 individuals live with IPF, and Europe has a comparable number. Worldwide, the figure is believed to exceed 1 million people living with IPF. Given how high the five-year death rate is for IPF, both physicians and their patients want more than just slowing disease progression — they also want a better quality of life. Right now, no treatments have been cleared for this severe illness. Our ongoing Phase 2 trial uses a double-blind crossover design, with 14 days of washout separating every three-week treatment period. For the primary endpoint, we assess the mean percent change from baseline in daytime cough frequency. That frequency is captured through a digital cough monitor, comparing the treatment and placebo groups. Right now, this study is taking place in the UK. Since this patient population is viewed as high risk, if they catch COVID-19 because of their lung impairment, COVID-19 restrictions have hit this trial harder than our PN study. We're glad to see shelter-in-place rules for these patients in the UK, which came out in early December, being lifted. Because of their condition, IPF patients were given priority for COVID vaccinations. We figure that most of them have now gotten all their shots. We've been coordinating very closely with our sites to figure out schedules for getting clinical research going again for this trial. We're watching clinics start to reopen and staff come back for research. A large portion of our team members and study investigators were given priority assignments caring for individuals with COVID-19 during the last twelve months. As of now, multiple locations have gotten the green light to restart their clinical research activities. It's heartening that a number of these locations are already identifying potential subjects for our study, and we anticipate that people will begin joining the trial again during this quarter. We'll keep collaborating tightly with every one of our other approved sites across the UK so that the study can reach full enrollment and get underway. As a reminder to all, the target for this trial is approximately 60 people signing up, with the goal being 44 who make it all the way through. Therefore, should sign-ups begin to build momentum, we believe strongly that the trial will reach completion. Quick update on Germany: you may recall that Trevi was pursuing potential clearances from regulators and ethics boards so it could establish study locations in that country. That effort progressed nicely. Even so, since the anticipated timeline and costs of activating those additional sites are considerable, we've decided against launching further clinical sites in Germany. Instead, now that pandemic-related limits have loosened in the United Kingdom, we're focused on completing enrollment there. Having covered where each trial currently stands, I'll now take you through our first-quarter 2021 financial results. To repeat, the complete financials for Q1 2021 are available in the press release we issued before this call and in our 10-Q, filed with the SEC today after market close. For Q1 2021, our net loss came in at $8.4 million, versus a net loss of $8.5 million in the comparable quarter of 2020. Research and development expenses were $5.6 million in Q1 2021, compared with $6 million in the same period of 2020. That decline stemmed mainly from fewer purchases of clinical trial supplies, which largely reflects timing and the wrap-up of our Phase 1b clinical trial in patients with chronic liver disease conducted a year ago. Some of that decrease was counterbalanced by more enrollment and activity in the PRISM trial we're currently running, plus increased costs tied to personnel, consulting, and professional services. G&A costs totaled $2.5 million during Q1 2021, compared with $2.6 million across the corresponding stretch of 2020. That drop stemmed mainly from a smaller stock-based compensation charge. Our overhead has generally kept us on a relatively stable runway. Cash and cash equivalents stood at $41.6 million on March 31, 2021, a decline from $45 million as of December 31, 2020. We anticipate that the cash we hold today will be sufficient to support operations through the second quarter of 2022. In addition to the revenue figures we anticipated from the PRISM study, and even though we'll require one or two more quarters of patient sign-ups before we can understand the timelines for cough enrollment now that COVID-19 limits are being removed, we believe it can also carry us all the way to completing enrollment in the cough trial. That wraps up all I had ready to say. I'll turn things back over to the operator now so we can move into questions.

Annabel Samimy

analyst
#2

Hi there, and thanks for getting us that update so quickly. What I'd like to do is step back and ask something broader regarding how you're approaching the opioid angle. The mechanism isn't exactly identical, but my sense is that the oral kappa opioid receptor did provide validation and demonstrated activity across two predict populations. So at minimum, there does appear to be something meaningful when it comes to the kappa route; and of course I understand yours differs somewhat because it involves a dual mechanism. Still, what I think we now have proof of is that the behavior of these two predict populations is genuinely quite hard to pin down; and I'd argue that even within an AD population, where the itch is extremely consistent, grasping how different itch populations behave remains quite challenging. So what sorts of things can you take away from those studies, and what steps can you take to, I suppose, handle what may turn out to be an extremely variable population, including in PN, where itch is so central to the condition? Maybe you could just address that in fairly broad terms.

Jennifer Good

executive
#3

Yes. Go ahead, Bill.

Bill Forbes

executive
#4

Sure. Thank you, Jennifer. And thank you, Annabel, for raising that. Allow me to walk through it, since we have clearly spent considerable time considering this. The kappa that you might be referring to, I believe, is in fact an opioid peptide. With the oral version of nalbuphine we've developed, the molecule behaves extremely predictably when it comes to absorption, distribution, metabolism, and excretion, as you're aware. Within our dosing range, the formulation scales linearly, and compared with the injectable version that has been sold for many decades, it extends the half-life. It lengthens it from 2 to 9 hours. So nalbuphine's safety profile is thoroughly characterized. As an injectable, it has decades of use behind it. More than 800 patients have been treated with the oral form in controlled clinical trials. So from a number of angles, when we examine safety and efficacy, our small molecule performs very reliably. When we consider the various patient populations, one area where we've excelled with this formulation and this product is demonstrating dose response. Our data in uremic pruritus is central to that; based on that trial of 373 patients, we know the drug appears safe and works quite well, and its efficacy rises with dose in a manner that is statistically significant. So when we begin comparing various kappa agonists — and ours is a dual mechanism, so you're correct that the mechanism here isn't identical — we still believe there are ongoing results indicating that this portion of the mechanism succeeds in treating pruritus. Our view is that because our drug acts both peripherally and centrally, it could have a considerably better effect, since we believe the itch pathway involves opioid receptors located on the skin, in peripheral neurons, in the spinal cord, and extending all the way to the brain. Being able to reach all of those regions and deliver efficacy is something we feel good about. So regarding the demonstration of meaningful benefit across these populations, they are hard to treat, which is exactly why we prefer our mechanism over some competitors, and perhaps I'll stop there. And if you have any questions.

Annabel Samimy

analyst
#5

One last thing regarding the PN patient group — that specific PN group, is their itching variable to the point where it might occasionally ease up, might show a placebo effect, might do anything within that group that ought to worry us?

Bill Forbes

executive
#6

The manner in which we enrolled this specific trial, I'd say, one factor among what we did — the challenge with bringing these patients in is that we want a uniform set of patients who at baseline score 7 or higher on the WI-NRS, and since that measure runs from 0 to 10, it's a scale with 11 points; and no score below 6 is permitted for them. So at baseline they truly appear — their scores seem highly consistent. Naturally, after entering the trial, we expect a treatment effect from the drug, yet I'd say largely what we have here is a reasonably steady and uniform group; that doesn't mean a placebo effect is absent. In PN trials, the placebo effect may reach roughly 20%.

Jennifer Good

executive
#7

Okay, Bill, one thing I'd throw in — and Annabel, my sense is what you're really getting at is: are there aspects of PN that make us uneasy? What I've mulled over as time has gone on is that clearly many things sit underneath the itch — atopic derm, uremic pruritus, and at times the cause is unknown — which creates those differing kinds of variability. And I realize the FDA will want to look into that. Given that our drug acts both centrally, as Bill said, and peripherally, I believe that helps in this regard, though it will be worth watching. With our Phase 2 results, we observed no distinctions based on whatever the trigger happened to be, yet that's something I always keep in mind — even though every one of them has PN and expects to make it through, we push for as uniform a population as possible, since there are underlying illnesses that set off PN to begin with.

Annabel Samimy

analyst
#8

All right, that's helpful.

Gary Nachman

analyst
#9

Hello, and good afternoon. Between the prior quarter and this one, your enrollment moved from roughly two-thirds to 70% across a span of several months. That's clearly meaningful movement, yet the speed of bringing patients in seems to have stalled somewhat. You noted that the data timeline might slip a bit further owing to the summer slowdown, but I'd like to know what you've observed over these recent months.

Jennifer Good

executive
#10

Bill, would you like to address that?

Bill Forbes

executive
#11

Yeah.

Jennifer Good

executive
#12

Yeah, go ahead.

Bill Forbes

executive
#13

Well, as you mentioned and like Jennifer said before, clearly we shifted our guidance from Q3 over to the second half. So something we're sort of observing is a bit of rubber banding when it comes to enrollment, looking at it month by month. That makes us — I think what really gives us confidence is when we speak with our study staff, both the study staff and the investigators, what we're hearing is that they feel very positive about being able to keep things moving along at a good pace. But we did want to attempt to provide the best guidance we possibly can, and clearly we'll keep updating guidance as things progress here. That said, I feel good that the centers are fully engaged. We're in touch with them very regularly, on a daily basis, and we hear back from them. They are pushing as hard as they can, but as we move into — as Jennifer said — as we look at the summer months approaching, we expect there could be some challenges with folks trying to take vacation, both on the study staff side and on the patient enrollment side, so.

Jennifer Good

executive
#14

Right, and I'd also mention, Gary, that as you're aware, our previous report came just 6 weeks back. So at times it simply depends on where you draw the line, and we do tend to round things off. So sure, it fluctuates, yet on the whole I'd say we've typically been landing near that 15 — at times it's 12, at times it's 20 — but it keeps tending to settle around that figure.

Bill Forbes

executive
#15

To respond to what you asked in a somewhat more straightforward way, my attention tends to be on the past 2 months or so. Enrollment during those recent 2 months appears to be roughly matching some of the strongest months from the year before, or thereabouts; so we take some encouragement from how things went over those recent 2 months, though as we look ahead, it's clear we still need to keep growing enrollment while moving through a challenging stretch during the summer months.

Gary Nachman

analyst
#16

Yeah. So, regarding that final item, Bill, when it comes to one or many of these PN patients who show up at these locations, where exactly do you feel you need to spark that, I’m not sure, excitement or awareness within the community, so what programs do you have in place to perhaps speed things up, particularly once summer arrives. And then, Jennifer, I believe you said you’re at 60 sites — is there any possibility you could elaborate on that, or it seems like you’re quite satisfied with the sites you have now, but do you think you might require a larger number of sites out there?

Jennifer Good

executive
#17

Go ahead, Bill.

Bill Forbes

executive
#18

Right, so let me address site count. We're constantly watching this, and a few sites are still in the process of joining. So it isn't as though we've stopped adding sites, but we've seen a great deal of strong activity, especially in the U.S., Germany and Poland — those countries have carried much of the load on this study — and we're seeing momentum build in our other countries, France and Austria. So from the site standpoint, I'd say we believe the horses we currently have can get us through this final stretch of enrollment. When it comes to the initiatives we run, we do what you would expect from us. We do a great deal of advertising. We keep refining it, and we learn what works and what doesn't. Some sites are extremely successful with it, and there are sites we're still working with to try to find a better approach to advertising and recruiting them; but at the site level, as far as the initiatives we've undertaken, we began rolling those out in February and March. And they're taking hold now; so I think in many ways, we're — hopefully we'll see the fruition of all of that and try to drive this home. But trust me, each day we wake up, this is what we ask; and it's what our investigators and coordinators and study staff are hunting. So we're pushing as hard as we can.

Gary Nachman

analyst
#19

All right, and one more brief item regarding IPF. It's encouraging to observe things starting to move there and that you're making some headway, but what number of sites has restarted screening, and in this case, how many remain that you need to bring back if the focus is going to be only on the UK? And is there another fallback option if the UK proves insufficient — if Germany doesn't add up, would you revisit Germany down the line? You appear fairly sure you can complete it within the UK, but I just wanted that confirmed. Thanks.

Bill Forbes

executive
#20

Yes. I believe this was clearly a strategic management decision, given how we assess the timelines for getting centers open in Germany — how long finishing that process would require and how much time the German investigators would have available to enroll. So we intend to actually shift away from Germany, and what we'll examine is adding sites within the UK. And I'd say at present roughly one third of the sites appear to be involved in screening right now, with the remainder still coming on. I think June will be a very good month for us to figure out precisely who is fully participating. And we have calls arranged with the investigators and the study staff to walk through how to achieve this. And I think the fact that screening is underway now will hopefully lead to some randomizations in the not too distant future, but that's the nature of screening — sometimes not everybody gets through; yet we feel good that the centers are engaging, they're ready to return to work, to pivot away from COVID, as you know these are pulmonary centers in the UK, so they got pulled into that side of the COVID treatment nightmare. And so, as they come back and perform their day job here doing research, we're looking forward to getting some good activity out of this during the June, July timeframe.

Gary Nachman

analyst
#21

All right, that's helpful — appreciate the extra detail.

Jennifer Good

executive
#22

Thank you, Gary.

Serge Belanger

analyst
#23

Good afternoon. I have a few questions. Perhaps this was covered in your prepared remarks and I missed it. Is there any news about patients transitioning into the extension study, and are discontinuations showing a similar pattern? Also, is there anything to learn from the Cara study that came out recently? I realize it involves a different itch condition, yet the endpoint is comparable, so is there any information regarding the placebo effect from that trial that might help us as we anticipate the PRISM readout? Thank you.

Jennifer Good

executive
#24

Let me offer a few thoughts, and then please share your perspective. Serge, I would gladly read my script back to you privately, telling you to remove all of it. But we did — we remain above 95%. Those who get through the study have done very well, staying enrolled and not merely transitioning, but continuing all the way to completion, receiving treatment for a year, since as you know these patients lack other options. Regarding discontinuations, and Bill can provide additional detail, I would say it matches our expectations, and I believe we've kept bringing that number down. Bill, you might want to address that point in connection with the SSRE; but on the Cara trials, since I reviewed them too, Serge, along with that — their placebo effects have actually fallen within the same range we've generally observed in these studies. I think they were, what, 19%, 20%; so I think that's useful. My own view on Cara, my personal bias, is that I trust the opioid mechanism, I believe kappa agonists are effective. As Bill mentioned during his remarks, the difficulty for Cara, apart from its injectable form, is whether they truly have the oral version figured out. And I think demonstrating that convincingly has been a struggle for them. So much of it seemed confirmatory to me, and atopic derm is a difficult indication. Numerous multifactorial elements are at play there, involving inflammation, itch, and other factors. But — those are my reflections. Bill, please add your own thoughts too.

Bill Forbes

executive
#25

Right. I suppose she already addressed most of it, so I'll just add a bit of color. Still, if you look at their trial, they clearly had an interim review, and ultimately they selected a dose — meaning they had 3 active doses against placebo. That isn't what happened in our case; what we did was a sample size re-estimation. As I mentioned earlier, since both the formulation and the molecule behave well, we already knew our dose before entering the study. That meant there was no need to worry about choosing among different doses. All we needed was to confirm we had the promised conditional power and then arrive at what the final end for the study should be. So we landed on a power of 360 total patients, 180 per treatment group. I believe Cara wound up with roughly 120 patients per group across the two doses, placebo and whichever active dose they picked. So, as we consider those results — a different indication, as you noted earlier, Serge — we always have to be cautious about that. They do enroll patients scoring a seven or greater on the edge gauge scale; we likewise enroll those at number seven or greater on our WI-NRS. Even so, in many respects, we feel good about where we stand. We feel powered up, and we feel we've got our dose.

Serge Belanger

analyst
#26

Excellent, thanks.

Jennifer Good

executive
#27

Thanks to all of you for joining us on this call today. I also want to express gratitude to the folks at Trevi, the investigators involved in our studies, and every other subject who remains involved in the clinical trials we are running. Enjoy the summer, everyone. Thanks.

Operator

operator
#28

Appreciate it, ma'am; this call is now part of the record. Everyone, thanks for joining us for today's presentation. At this point you're free to hang up, and we hope the rest of your day is great.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.